Related references
Note: Only part of the references are listed.Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1
Christopher E. M. Griffiths et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2022)
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis
Andrew Blauvelt et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)
Long-term survival of biological therapy in psoriatic arthritis: 18-year analysis of a cohort in a tertiary hospital
Lourdes Mateo Soria et al.
RHEUMATOLOGY INTERNATIONAL (2022)
Efficacy and Safety of Guselkumab, an Interleukin-23p 19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis
Iain B. McInnes et al.
ARTHRITIS & RHEUMATOLOGY (2021)
GUSELKUMAB TREATMENT MODULATES CORE PSORIATIC ARTHRITIS GENE EXPRESSION IN TWO PHASE 3 CLINICAL TRIALS (DISCOVER-1 AND-2)
S. Siebert et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials
Kristen Sweet et al.
RMD OPEN (2021)
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naive or TNFα inhibitor-experienced
Christopher T. Ritchlin et al.
RMD OPEN (2021)
Long-term remission and biologic persistence rates: 12-year real-world data
Kieran Murray et al.
ARTHRITIS RESEARCH & THERAPY (2021)
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial
Philip J. Mease et al.
LANCET (2020)
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
Atul Deodhar et al.
LANCET (2020)
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study
Kristian Reich et al.
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2020)
Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting
Philip J. Mease et al.
RHEUMATOLOGY INTERNATIONAL (2019)
Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial
Kristian Reich et al.
LANCET (2019)
Psoriatic arthritis 1 The pathogenesis of psoriatic arthritis
Douglas J. Veale et al.
LANCET (2018)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis
Laura C. Coates et al.
ARTHRITIS & RHEUMATOLOGY (2018)
The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
Andrew Blauvelt et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2018)
Switching biologics in the treatment of psoriatic arthritis
Joseph F. Merola et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2017)
Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry
Leslie R. Harrold et al.
CLINICAL RHEUMATOLOGY (2017)
Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments
Laura C. Coates et al.
JOURNAL OF RHEUMATOLOGY (2016)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Laura C. Coates et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial
Laura C. Coates et al.
LANCET (2015)
The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials
Richard G. B. Langley et al.
JOURNAL OF DERMATOLOGICAL TREATMENT (2015)
Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment
L. C. Coates et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Regulation of the Psoriatic Chemokine CCL20 by E3 Ligases Trim32 and Piasy in Keratinocytes
Yuangang Liu et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2010)
Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis
Nikhil Yawalkar et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2009)
Th17 Cytokines Stimulate CCL20 Expression in Keratinocytes In Vitro and In Vivo: Implications for Psoriasis Pathogenesis
Erin G. Harper et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Measuring clinical enthesitis in psoriatic arthritis: Assessment of existing measures and development of an instrument specific to psoriatic arthritis
Paul J. Healy et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis - Results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
CE Antoni et al.
ARTHRITIS AND RHEUMATISM (2005)
Psoriatic arthritis imaging: a review of scoring methods
D van der Heijde et al.
ANNALS OF THE RHEUMATIC DISEASES (2005)
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris
E Lee et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Share Paper
